United States · Markets & Finance · Yahoo Finance

Iambic Therapeutics (IAM) Filed An IND For IAM217

Published by Yahoo Finance · United States 10 h ago

Iambic Therapeutics (NasdaqGS:IAM) submitted an Investigational New Drug application to the FDA for IAM217, a KIF18A inhibitor, in October 2026. IAM217 is described by the company…

Read the full article on Yahoo Finance Sign in to save

MediaNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (finance.yahoo.com)

Also worth reading

Cointelegraph

France is aflame as peaceful protests over the cost of living devolve into chaos and looting

CoinDesk

Circle defends USDC economics as stablecoin rivals court its partners with bigger cut

Seeking Alpha

Iambic Therapeutics (IAM) Filed An IND For IAM217

Share

Also worth reading

Tether backs AIsa as strategic investor, completing seed extension round

Why hedge funds could be making a bond market shock more likely

Americans are packing town halls to stop data centers. It's working, for now

France is aflame as peaceful protests over the cost of living devolve into chaos and looting

Circle defends USDC economics as stablecoin rivals court its partners with bigger cut

New England faces record-high heating oil costs this winter